Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment
出版年份 2023 全文链接
标题
Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 7, Pages 6495
出版商
MDPI AG
发表日期
2023-03-31
DOI
10.3390/ijms24076495
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Recent Advances in Cancer Immunotherapy Delivery Modalities
- (2023) Palaniyandi Muthukutty et al. Pharmaceutics
- The role of tumor-infiltrating lymphocytes in cholangiocarcinoma
- (2022) Dong Liu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape
- (2022) Qinghua Wu et al. Journal of Hematology & Oncology
- Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
- (2022) Alessandro Rizzo et al. Expert Review of Gastroenterology & Hepatology
- SOCS3 Acts as an Onco-immunological Biomarker With Value in Assessing the Tumor Microenvironment, Pathological Staging, Histological Subtypes, Therapeutic Effect, and Prognoses of Several Types of Cancer
- (2022) Lirui Dai et al. Frontiers in Oncology
- Comparative assessment of early mortality risk upon immunecheckpoint inhibitors alone or in combinations with other agents across solid malignancies: a systematic review and meta-analysis
- (2022) Giuseppe Viscardi et al. EUROPEAN JOURNAL OF CANCER
- In Vivo Oncolytic Virotherapy in Murine Models of Hepatocellular Carcinoma: A Systematic Review
- (2022) Muhammad Joan Ailia et al. Vaccines
- Intratumoral Hypoxia and Mechanisms of Immune Evasion Mediated by Hypoxia-Inducible Factors
- (2021) Gregg L. Semenza PHYSIOLOGY
- Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer
- (2021) Gaopeng Li et al. Journal for ImmunoTherapy of Cancer
- Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
- (2021) Vishakha Singh et al. Frontiers in Pharmacology
- Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
- (2021) Alessandro Rizzo et al. Frontiers in Oncology
- Targeting hypoxia in tumor: a new promising therapeutic strategy
- (2020) Maria Carla Bosco et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B
- (2020) George V. Papatheodoridis et al. JOURNAL OF HEPATOLOGY
- Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms
- (2020) Mu-Yang Huang et al. PHARMACOLOGY & THERAPEUTICS
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Programmed death-ligand 1 expression in the tumour stroma of colorectal liver oligometastases and its association with prognosis after liver resection
- (2020) Jian-Hong Peng et al. Gastroenterology Report
- Pharmacologic Targeting of Hypoxia-Inducible Factors
- (2019) Gregg L. Semenza Annual Review of Pharmacology and Toxicology
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
- (2019) Jérôme Galon et al. NATURE REVIEWS DRUG DISCOVERY
- A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer
- (2019) Zhongyuan Fan et al. OncoTargets and Therapy
- Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer
- (2019) Xiaobin Gu et al. Cancer Cell International
- PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma
- (2019) Jessica Carlsson et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Application of PD-1 Blockade in Cancer Immunotherapy
- (2019) Xiaomo Wu et al. Computational and Structural Biotechnology Journal
- Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
- (2019) Rachael M. Zemek et al. Science Translational Medicine
- Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
- (2019) Haotian Liao et al. Frontiers in Oncology
- PD-1+ TIGIT+ CD8+ T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma
- (2019) Xiaoli Liu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients
- (2018) Boyang Chang et al. LIVER INTERNATIONAL
- Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma
- (2018) Xiaomeng Dai et al. Translational Oncology
- Immunotherapy of Hepatocellular Carcinoma
- (2018) Bernd Heinrich et al. Oncology Research and Treatment
- Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma
- (2018) Xue Han et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
- (2018) Boyang Chang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
- (2018) Yaxiong Zhang et al. Journal for ImmunoTherapy of Cancer
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
- (2017) Daniela Sia et al. GASTROENTEROLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma
- (2017) So Young Yoo et al. MEDIATORS OF INFLAMMATION
- Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma
- (2017) Jianhua Liu et al. ONCOLOGY REPORTS
- Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection
- (2017) Na Li et al. Oncotarget
- PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load
- (2017) Yajuan Zhou et al. Scientific Reports
- Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
- (2017) Hae Il Jung et al. Cancer Research and Treatment
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma
- (2016) Yih-Leong Chang et al. EUROPEAN JOURNAL OF CANCER
- High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
- (2016) Fabian Finkelmeier et al. EUROPEAN JOURNAL OF CANCER
- Hypoxia-inducible factors: a central link between inflammation and cancer
- (2016) Daniel Triner et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines
- (2016) Jingwei Liu et al. JOURNAL OF IMMUNOTHERAPY
- Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
- (2016) A. Gabrielson et al. Cancer Immunology Research
- The yin and yang of evasion and immune activation in HCC
- (2015) Oxana V. Makarova-Rusher et al. JOURNAL OF HEPATOLOGY
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
- (2015) Tao Qin et al. Oncotarget
- Mechanisms of Hypoxia-Mediated Immune Escape in Cancer
- (2014) I. B. Barsoum et al. CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- The immune contexture of primary and metastatic human tumours
- (2014) Nicolas A Giraldo et al. CURRENT OPINION IN IMMUNOLOGY
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
- (2013) Gabriela Bindea et al. IMMUNITY
- Targeted Therapies for Hepatocellular Carcinoma
- (2011) Augusto Villanueva et al. GASTROENTEROLOGY
- Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma
- (2011) Zhen Zeng et al. PLoS One
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 signaling in primary T cells
- (2009) James L. Riley IMMUNOLOGICAL REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search